BC
BCLI.US Brainstorm Cell Therapeutics Inc
- Market cap
- USD 10.9M
- P/E
- -
- P/B
- 54.50x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BCLI.US undervalued?
Graham numberThe Graham number of Brainstorm Cell Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Brainstorm Cell Therapeutics Inc fundamental analysis
No fundamental analysis for Brainstorm Cell Therapeutics Inc yet.
Brainstorm Cell Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal …
Full company profileBrainstorm Cell Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Brainstorm Cell Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | -366K | 0.00 | 0.00 | 0.00 | 0.00 | 849K | 703K | 356K |
| Gross Profit | -77.0K | -85.0K | -110K | -732K | -219K | -260K | -285K | -265K | -240K | - | -166K |
| Operating Income | -5.08M | -5.00M | -14.1M | -23.0M | -31.7M | -24.5M | -24.8M | -21.4M | -11.7M | -9.95M | -11.3M |
| EBITDA | -4.91M | -4.87M | -13.8M | -23.1M | -31.5M | -24.3M | -24.5M | -16.9M | -11.3M | -9.75M | -11.2M |
| Net Income | -4.98M | -4.95M | -13.9M | -23.3M | -31.8M | -24.5M | -23.7M | -17.2M | 11.6M | -10.3M | -12.0M |
| EPS | -4.00 | -3.92 | -10 | -14 | -14 | -10 | -9.71 | -4.48 | 2.19 | -1.11 | -1.08 |
| Balance Sheet | |||||||||||
| Total Assets | 10.8M | 11.4M | 11.2M | 6.53M | 51.3M | 29.3M | 8.45M | 4.21M | 1.83M | 715K | 472K |
| Total Liabilities | 864K | 5.54M | 6.21M | 18.8M | 15.8M | 9.94M | 11.5M | 9.07M | 9.60M | 11.0M | 12.4M |
| Shareholders' Equity | 9.90M | 5.88M | 5.02M | -12.2M | 35.5M | 19.3M | -3.02M | -4.86M | -7.76M | -10.3M | -11.6M |
| Cash & Short-term Investments | 9.99M | 7.76M | 7.06M | 569K | 41.9M | 22.1M | 2.98M | 1.30M | 187K | 29.0K | 22.0K |
| Total Debt | - | - | - | 2.37M | 7.22M | 5.08M | 4.09M | 1.28M | 720K | 208K | 1.37M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.86M | -2.36M | -12.4M | -11.2M | -35.2M | -26.3M | -19.3M | -20.5M | -9.09M | -6.98M | -4.43M |
| Capital Expenditure | 103K | 180K | 369K | 473K | 378K | 330K | 29.0K | 18.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -5.96M | -2.54M | -12.8M | -11.7M | -35.6M | -26.6M | -19.3M | -20.5M | -9.09M | -6.98M | -4.43M |
| Ratios | |||||||||||
| ROE | -50.3% | -84.2% | -278.1% | - | -89.7% | -126.4% | - | - | - | - | - |
| ROA | -46.3% | -43.4% | -124.2% | -355.9% | -62.1% | -83.5% | -280.8% | -408.6% | 634.4% | -1,441.5% | -2,534.7% |
| Net Profit Margin | - | - | - | - | - | - | - | - | 1,369.0% | -1,466.1% | -3,360.7% |
| Debt to Equity | - | - | - | - | 0.20x | 0.26x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Brainstorm Cell Therapeutics Inc dividends
Brainstorm Cell Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Oct 1, 2024.
Who owns Brainstorm Cell Therapeutics Inc
- Insiders 8.68%
- Institutions 0.00%
- Public & others 91.32%
- Shares outstanding 11.0M
- Free float 10.3M
Top funds holding BCLI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Extended Equity Market Fund B | 4.80K | 0.04% | 0.00% | Jun 2025 |
Top institutions holding BCLI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Dec 2025 |
| VSM Wealth Advisory, LLC | 0.00 | 0.00% | -100.00% | Dec 2025 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Dec 2025 |
| St Germain D J Co Inc | 0.00 | 0.00% | -100.00% | Dec 2025 |
| Steward Partners Investment Advisory, LLC | 0.00 | 0.00% | -100.00% | Dec 2025 |
| Bangor Savings Bank | 0.00 | 0.00% | -100.00% | Dec 2025 |
Brainstorm Cell Therapeutics Inc company profile
- Company name
- Brainstorm Cell Therapeutics Inc
- Ticker
- BCLI.US
- Exchange
- USA Stocks
- Listed since
- Aug 28, 2003
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 1325 Avenue of Americas, New York, NY, United States, 10019
- Phone
- 201 488 0460
- Website
- brainstorm-cell.com
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Brainstorm Cell Therapeutics Inc management
7- Mr. Chaim LebovitsPresident & CEO · born 1971
- Mr. Uri YablonkaExecutive VP, Chief Business Officer, Secretary & Director · born 1977
- Mr. Peter J. PittsChief Strategic Regulatory and Policy Officer & Executive Chairman · born 1959
- Ms. Alla Patlis CPA, M.B.A.Interim CFO & Controller · born 1987
- Dr. Hartoun Hartounian Ph.D.Executive VP & COO · born 1960
- Ms. Mary Kay TurnerSenior Vice President of Patient Advocacy & Government Affairs
- Dr. Netta Blondheim-Shraga Ph.D.Senior Vice President of Research and Development